BRPI0408236A - método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer - Google Patents

método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer

Info

Publication number
BRPI0408236A
BRPI0408236A BRPI0408236-2A BRPI0408236A BRPI0408236A BR PI0408236 A BRPI0408236 A BR PI0408236A BR PI0408236 A BRPI0408236 A BR PI0408236A BR PI0408236 A BRPI0408236 A BR PI0408236A
Authority
BR
Brazil
Prior art keywords
compound
human
animal body
monitoring
generating
Prior art date
Application number
BRPI0408236-2A
Other languages
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Joseph Maduabuchi Arukwe
Hege Karlsen
Matthias Eberhard Glaser
Original Assignee
Amersham Health As
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As, Hammersmith Imanet Ltd filed Critical Amersham Health As
Publication of BRPI0408236A publication Critical patent/BRPI0408236A/pt
Publication of BRPI0408236B1 publication Critical patent/BRPI0408236B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B39/00—Halogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02—Preparation of hydrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/14—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/66—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/48—Preparation of compounds having groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/48—Preparation of compounds having groups
    • C07C41/50—Preparation of compounds having groups by reactions producing groups
    • C07C41/56—Preparation of compounds having groups by reactions producing groups by condensation of aldehydes, paraformaldehyde, or ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/55—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA RADIOFLUORAçãO, COMPOSTO, COMPOSIçãO RADIOFARMACêUTICA, USO DE UM COMPOSTO, E, MéTODOS PARA GERAR UMA IMAGEM DE UM CORPO HUMANO OU ANIMAL E PARA MONITORAR O EFEITO DE TRATAMENTO DE UM CORPO HUMANO OU ANIMAL COM UM MEDICAMENTO PARA COMBATER UMA CONDIçãO ASSOCIADA COM CáNCER" invenção refere-se a conjugados de Fórmula (V) ou (VI): em que X é -CO-NH-, -NH-, -O-, -NHCONH-, ou -NHCSNH-; seu uso como compostos radiofarmacêuticos, processos para sua preparação e intermediários sintéticos usados em tais processos.
BRPI0408236A 2003-03-13 2004-03-12 método para radiofluoração, composto, composição radiofarmacêutica, e, uso de um composto BRPI0408236B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305704.9A GB0305704D0 (en) 2003-03-13 2003-03-13 Radiofluorination methods
PCT/GB2004/001052 WO2004080492A1 (en) 2003-03-13 2004-03-12 Methods of radiofluorination of biologically active vectors

Publications (2)

Publication Number Publication Date
BRPI0408236A true BRPI0408236A (pt) 2006-03-01
BRPI0408236B1 BRPI0408236B1 (pt) 2016-09-20

Family

ID=9954659

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408236A BRPI0408236B1 (pt) 2003-03-13 2004-03-12 método para radiofluoração, composto, composição radiofarmacêutica, e, uso de um composto

Country Status (19)

Country Link
US (1) US8197793B2 (pt)
EP (1) EP1601384B1 (pt)
JP (1) JP4855924B2 (pt)
KR (1) KR101066684B1 (pt)
CN (1) CN100586485C (pt)
AT (1) ATE481987T1 (pt)
AU (1) AU2004218879B2 (pt)
BR (1) BRPI0408236B1 (pt)
CA (1) CA2518889C (pt)
DE (1) DE602004029237D1 (pt)
ES (1) ES2352731T3 (pt)
GB (1) GB0305704D0 (pt)
IL (1) IL170339A (pt)
MX (1) MXPA05009682A (pt)
NO (1) NO333174B1 (pt)
PL (1) PL1601384T3 (pt)
RU (2) RU2363704C2 (pt)
WO (1) WO2004080492A1 (pt)
ZA (1) ZA200507849B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
GB0420365D0 (en) * 2004-09-14 2004-10-13 Hammersmith Imanet Ltd Radiolabelled insulin
JP2009508090A (ja) * 2005-08-31 2009-02-26 イムノメディクス， インコーポレイテッド 予め標的化されたポジトロン放出断層撮影画像化のためのｆ−１８ペプチド
JP2009541288A (ja) * 2006-06-21 2009-11-26 ハマースミス・イメイネット・リミテッド 放射性標識方法
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
KR20090085599A (ko) * 2006-10-02 2009-08-07 바이엘 쉐링 파마 악티엔게젤샤프트 Ｐｅｔ 영상화용 규소 유도체
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
WO2008072973A2 (en) * 2006-12-11 2008-06-19 Ge Healthcare As Radiolabelled peptide based compounds and uses thereof
EP2099499A2 (en) 2006-12-13 2009-09-16 GE Healthcare AS Synthesis of a radiofluorinated peptide using microwave activation technology
US8241606B2 (en) * 2006-12-18 2012-08-14 Ge Healthcare As Synthesis of a radiofluorinated peptide using photolabile protecting groups
JP4989241B2 (ja) * 2007-01-29 2012-08-01 静岡県公立大学法人 ［１８ｆ］標識化合物及びその製造方法、並びに［１８ｆ］標識リポソーム及び［１８ｆ］標識リポソーム製剤の製造方法
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Aktiengesellschaft Métodos de radiofluoração
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8415510B2 (en) * 2008-02-28 2013-04-09 Ge Healthcare Limited Synthesis of a PEG-6 moiety from commercial low-cost chemicals
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
GB0819293D0 (en) * 2008-10-21 2008-11-26 Hammersmith Imanet Ltd Radiofluorination
GB0819280D0 (en) * 2008-10-21 2008-11-26 Gen Electric Imgaing and radiotherapy methods
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
GB0901483D0 (en) * 2009-01-29 2009-03-11 Ge Healthcare Ltd Radioiodination method
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0905515D0 (en) * 2009-03-31 2009-05-13 Ge Healthcare Ltd Radiolabelling methods
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
US20120229804A1 (en) 2009-12-21 2012-09-13 Medi-Physics, Inc. Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f- ion
EP2515949A1 (en) * 2009-12-22 2012-10-31 GE Healthcare UK Limited Aldehydes for in vivo imaging of aldh in cancer stem cells
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
CA2819347A1 (en) 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
GB201020314D0 (en) * 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
JP6055417B2 (ja) 2010-12-09 2016-12-27 ジーイー・ヘルスケア・リミテッド 放射性トレーサー組成物
RU2013128354A (ru) 2010-12-21 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Применение анализа в радиостабилизации реакций оксимного лигирования
NZ612327A (en) 2010-12-22 2015-03-27 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
EP2654803B1 (en) 2010-12-22 2021-08-18 General Electric Company Radiolabeled her2-binding peptide conjugates
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
GB201205703D0 (en) 2012-03-30 2012-05-16 Ge Healthcare Ltd Synthon composition
GB201221266D0 (en) 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
KR102668112B1 (ko) 2014-12-04 2024-05-23 지이 헬쓰케어 리미티드 방사성 약제로부터의 아세트알데히드의 제거 방법
WO2020205544A1 (en) * 2019-03-29 2020-10-08 Cary Douglas D Use of ketone bodies medical imaging and diagnostics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837095T2 (de) * 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods

Also Published As

Publication number Publication date
CA2518889A1 (en) 2004-09-23
KR101066684B1 (ko) 2011-09-21
GB0305704D0 (en) 2003-04-16
RU2005126984A (ru) 2006-06-27
CN100586485C (zh) 2010-02-03
US20100068139A1 (en) 2010-03-18
KR20060002819A (ko) 2006-01-09
JP4855924B2 (ja) 2012-01-18
RU2009112412A (ru) 2010-10-20
CN1758925A (zh) 2006-04-12
IL170339A (en) 2012-02-29
AU2004218879A1 (en) 2004-09-23
DE602004029237D1 (de) 2010-11-04
NO333174B1 (no) 2013-03-25
ZA200507849B (en) 2007-09-26
WO2004080492A1 (en) 2004-09-23
US8197793B2 (en) 2012-06-12
JP2006523658A (ja) 2006-10-19
ATE481987T1 (de) 2010-10-15
MXPA05009682A (es) 2006-01-27
PL1601384T3 (pl) 2011-03-31
CA2518889C (en) 2015-11-03
HK1087928A1 (zh) 2006-10-27
EP1601384B1 (en) 2010-09-22
NO20054185L (no) 2005-11-10
EP1601384A1 (en) 2005-12-07
RU2363704C2 (ru) 2009-08-10
NO20054185D0 (no) 2005-09-09
BRPI0408236B1 (pt) 2016-09-20
AU2004218879B2 (en) 2009-10-01
ES2352731T3 (es) 2011-02-22

Similar Documents

Publication Publication Date Title
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BR0316906A (pt) administração do capsaicinoides
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
UY26269A1 (es) Formulación de sal común y moxifloxacina
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
TW200510373A (en) Substituted quinolin-4-ylamine analogues
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
TW200626608A (en) Macrolides
TR200101633T2 (tr) Farmasötik bileşim
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: HAMMERSMITH IMANET LTD (GB) , GE HEALTHCARE AS (NO

Free format text: ALTERADO DE: AMERSHAM HEALTH AS

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/09/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.